The team at SecureMeters in India have secured in-country regulatory approval for their UCL Ventura-based CPAP devices. They have successfully manufactured 40 CPAP devices so far, and these are being used in clinical trials in three hospitals across India.
They are planning to manufacture up to 200 devices initially. Their immediate next steps are to focus on supply to Maharashtra, an area of India where COVID-19 infections are rapidly increasing.
When the pandemic hit us, we realized that the UCL Ventura open source license offered us a quick route to serve the impacted communities. We were impressed by the simplicity of its design and its specific suitability to Covid19 patient applications. Although we did not have the market reach in the medical devices segment, our engineering expertise with mass production of complex smart meters and control products under strict process control norms suitable for the global market gave us the strength to jump into this venture. With the help of a very supportive team from UCL and Mercedes, we were successful in quickly developing the supply chain and manufacturing facilities for the CPAP p12 device. Our devices have been qualified against the UCL Ventura specifications and have received the necessary regulatory clearances in India. A few clinical trials have been done and we are seeing a growing interest in the markets. Being able to do our part in fighting this pandemic is a satisfying experience. Swati Doshi, SecureMeters
The company has had years of of Research & Developement experience in instrumentation and gas flow measurement techniques, which they leveraged to design and produce their CPAP p12 device.
Video above: SecureMeters has produced their own instructional video of the CPAP device and its features to support its clinical use
Director's Summer Reading List 2025
Recommendations for your Summer reading from IGP's Director, Professor Henrietta L. Moore.
23 Jun 2025
Digital Transformation in ATMP Manufacturing held at UCL East on 16 May
The event convened over 60 invited stakeholders across industry, NHS, academia, and regulation to address key barriers in the scaling of CAR-T and other advanced therapy medicinal products (ATMPs).
20 Jun 2025
New hub to harness the power of microbes to turn waste into valuable products
UCL Biochemical Engineering is part of a pioneering new hub that is set to transform UK manufacturing by converting industrial waste into valuable, sustainable chemicals and materials.
19 Jun 2025
